Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NoCanTher

Financiado

Cerrado

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project. The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct n... ver más

30/09/2021

FUNDACION IMDEA NA...

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

FUNDACION IMDEA NANOCIENCIA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-09-30

NMP-11-2015: Nanomedicine therapy for cancer Scope:Specific challenge: Promising pre-clinical nano-medicine proof-of-concepts have been developed...

I+D

Cerrada

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

FUNDACION IMDEA NANOCIENCIA

729.70K€ | Lider

MOEHS IBERICA

1.52M€ | Participante

FUNDACIO HOSPITAL UNIVERSITA...

630.63K€ | Participante

CHEMICELL GMBH

174.17K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 66 meses Fecha Inicio: 2016-03-08
Fecha Fin: 2021-09-30

Líder del proyecto

FUNDACION IMDEA NANOCIENCIA Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion

TRL 4-5 | 130K€

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project. The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer. NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities: • Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD). This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores